scanX
Lupin
add_icon

Lupin

2,302.10
+17.60
(0.77%)
Market Cap
1,05,215.92 Cr
PE Ratio
19.51
Volume
86,720.00
Day High - Low
2,304.50 - 2,281.30
52W High-Low
2,494.00 - 1,836.80
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
1,05,215.92 Cr
EPS
128.45
PE Ratio
19.51
PB Ratio
4.65
Book Value
490.98
EBITDA
7,787.60
Dividend Yield
0.79 %
Industry
Healthcare
Sector
Pharmaceuticals
Return on Equity
19.12
Debt to Equity
0.27
Analyst Rating and Forecast
- By Refinitiv from35 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+42.86 %
+42.86 %
Hold
Hold+37.14 %
+37.14 %
Sell
Sell+20.00 %
+20.00 %
Forecast For
Actual

Company News

View All News
Caret
positive
Lupin Debuts in Dow Jones Best-in-Class Indices 20262 days ago
Lupin Limited makes its first-ever inclusion in the Dow Jones Best-in-Class World and Emerging Markets Indices 2026, recognising its top-tier ESG performance and S&P Global CSA score of 91/100.
positive
Lupin Gets US FDA Tentative Nod for Refevenacin Solution3 days ago
Lupin receives tentative approval from the US FDA for Refevenacin Inhalation Solution, marking a regulatory milestone for the pharmaceutical company.
neutral
Lupin Sees Rs. 17.53 Cr Block Trade on NSE6 days ago
Lupin recorded a block trade on NSE worth Rs. 17.53 crores, involving approximately 76,709 shares transacted at a price of Rs. 2285.80 per share.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,894.40
#1 4,54,530.02
41.43
#1 54,729.00
9.71
#1 10,980
16.07
63.97
Divis Laboratories
6,837.00
1,81,500.87
73.47
9,712.00
18.67
2,191
-1.02
65.33
Torrent Pharmaceuticals
4,467.60
1,51,203.88
66.60
11,539.40
6.99
1,911
26.24
60.95
Cipla
1,401.20
1,13,186.23
29.32
27,711.70
-2.46
3,783
-55.32
62.59
Dr Reddys Laboratories
1,316.00
1,09,839.02
26.47
33,593.30
-0.44
3,998
-86.05
55.33
Lupin
2,302.10
#6 1,05,215.92
#1 19.51
#5 27,487.50
#2 19.98
#2 5,345
#1 87.72
47.68
Zydus Life Science
1,045.45
1,05,196.73
20.35
26,719.70
13.65
5,242
7.82
69.04
Mankind Pharma
2,501.10
1,03,246.68
53.58
14,277.60
12.03
1,750
31.75
66.76
Aurobindo Pharma
1,481.00
86,016.72
25.77
32,345.60
9.43
3,484
1.99
76.23
Laurus Labs
1,339.60
72,319.19
81.91
6,812.90
#1 21.03
884
21.18
79.63

Automatic Screeners on ScanX

Community
Resistance 1 Breached
Growth Rate
Revenue Growth
19.98 %
Net Income Growth
61.67 %
Cash Flow Change
-17.77 %
ROE
41.95 %
ROCE
20.69 %
EBITDA Margin (Avg.)
16.64 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Revenue
3,071
3,157
3,250
3,417
4,144
4,424
4,243
4,511
4,209
3,839
3,952
3,929
4,125
3,960
4,122
3,872
3,922
3,922
4,007
3,844
4,084
3,513
3,807
3,939
3,808
4,265
4,076
4,122
3,880
3,610
4,106
4,263
4,368
4,765
4,980
5,109
4,924
5,582
5,539
5,672
5,619
6,243
6,921
7,215
7,533
Expenses
2,289
2,331
2,667
2,702
2,883
3,157
3,260
3,264
3,472
3,104
3,099
3,287
4,789
3,329
3,401
3,608
3,107
3,131
3,788
3,629
3,320
3,040
3,254
3,239
3,066
3,306
5,415
3,791
3,615
3,512
3,693
3,790
3,852
3,958
4,121
4,160
3,964
4,359
4,332
4,412
4,346
4,541
4,706
5,332
5,120
EBITDA
783
825
583
715
1,261
1,268
983
1,246
737
735
853
642
-665
631
721
264
814
791
219
215
763
473
553
700
742
960
-1,339
331
265
98
414
473
515
807
859
950
960
1,223
1,207
1,261
1,273
1,702
2,215
1,883
2,412
Operating Profit %
25 %
24 %
16 %
19 %
30 %
27 %
23 %
26 %
17 %
18 %
20 %
16 %
-20 %
12 %
13 %
6 %
18 %
18 %
1 %
2 %
12 %
12 %
14 %
17 %
18 %
22 %
-35 %
7 %
6 %
3 %
10 %
11 %
11 %
17 %
17 %
18 %
19 %
21 %
21 %
21 %
22 %
26 %
31 %
25 %
31 %
Depreciation
107
101
116
122
149
203
211
231
267
261
272
280
273
259
266
219
219
250
253
253
214
215
213
244
216
209
919
203
327
193
204
220
264
235
248
257
457
248
257
272
393
299
317
313
447
Interest
3
7
24
10
31
35
29
48
41
44
48
54
59
69
74
79
84
84
83
89
107
44
34
31
32
34
34
33
42
43
55
84
93
86
81
74
71
68
71
67
89
92
108
115
120
Profit Before Tax
697
792
581
781
1,170
1,156
822
1,045
520
494
611
383
-941
384
441
93
591
518
-54
-73
496
273
360
525
518
751
-2,205
167
-85
2
210
246
259
559
630
736
498
993
1,055
1,071
896
1,416
2,007
1,522
1,928
Tax
136
224
158
255
417
273
159
410
137
137
154
161
-163
181
173
245
294
216
70
767
105
164
147
84
54
202
-110
-382
427
89
75
89
16
106
134
117
130
188
195
212
114
194
522
342
459
Net Profit
561
568
422
526
753
883
663
636
384
357
457
222
-778
203
269
-152
296
303
-123
-840
391
109
214
441
464
548
-2,095
549
-512
-87
135
158
242
453
495
619
368
806
860
859
782
1,222
1,485
1,181
1,469
EPS in ₹
12.17
12.65
9.34
11.67
16.63
19.57
14.69
14.04
8.42
7.93
10.07
4.91
-17.33
6.40
5.88
-3.37
6.55
6.69
-2.72
-18.56
8.64
2.36
4.66
9.67
10.15
11.96
-46.22
12.01
-11.40
-1.96
2.85
3.38
5.19
9.94
10.76
13.47
7.89
17.58
18.70
18.75
16.93
26.70
32.36
25.74
34.83
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Total Assets
13,138
22,625
26,607
26,305
27,949
24,984
23,610
21,821
22,956
23,997
29,205
38,365
Fixed Assets
4,368
8,717
11,033
10,362
11,087
7,938
7,881
7,382
8,355
8,878
9,719
9,352
Current Assets
7,832
9,887
11,953
12,210
13,854
15,413
13,986
12,458
12,451
13,448
16,799
24,027
Capital Work in Progress
576
2,702
2,133
2,598
1,640
940
1,066
1,146
1,238
773
517
695
Investments
1,656
16
2,136
262
2,296
2,374
2,455
900
517
1,075
1,146
6,083
Other Assets
6,538
11,189
11,305
13,084
12,928
13,732
12,209
12,393
12,846
13,272
17,823
0
Total Equity & Liabilities
13,138
22,625
26,607
26,305
27,949
24,984
23,610
21,821
22,956
23,997
29,205
38,365
Current Liabilities
3,729
5,061
6,121
5,096
6,130
9,225
8,436
8,498
9,265
8,502
8,961
12,651
Non Current Liabilities
510
6,368
6,955
7,593
8,030
3,178
1,316
1,101
1,148
1,122
2,949
3,200
Total Equity
8,898
11,196
13,532
13,617
13,789
12,581
13,858
12,222
12,543
14,374
17,294
22,448
Reserve & Surplus
8,784
11,073
13,407
13,487
13,652
12,446
13,712
12,062
12,374
14,199
17,112
22,357
Share Capital
90
90
90
90
91
91
91
91
91
91
91
91
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
1,502
-1,315
2,019
729
-872
1,685
-1,303
87
273
-248
560
Investing Activities
-1,034
-6,769
-2,527
470
-3,283
1,107
-1,240
1,292
-1,287
-1,712
-4,172
Operating Activities
2,733
-382
4,114
1,751
1,666
1,469
1,822
367
1,897
3,648
3,000
Financing Activities
-197
5,836
433
-1,492
744
-891
-1,885
-1,572
-337
-2,184
1,732
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Promoter
46.86 %
46.84 %
46.83 %
46.81 %
46.78 %
47.10 %
47.11 %
47.10 %
47.08 %
47.07 %
47.05 %
47.04 %
47.01 %
46.98 %
46.96 %
46.95 %
46.92 %
46.90 %
46.90 %
46.89 %
46.86 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
16.11 %
18.28 %
19.32 %
21.50 %
22.04 %
21.46 %
21.25 %
20.49 %
21.49 %
21.71 %
DIIs
22.08 %
21.68 %
24.38 %
24.76 %
26.84 %
26.82 %
27.54 %
29.38 %
29.21 %
28.98 %
29.42 %
29.73 %
27.76 %
26.78 %
25.09 %
24.74 %
25.41 %
25.56 %
26.55 %
25.58 %
25.32 %
Government
0.29 %
0.28 %
0.28 %
0.28 %
0.29 %
0.29 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.00 %
Public / Retail
10.02 %
9.91 %
10.18 %
9.99 %
8.53 %
8.59 %
8.41 %
8.06 %
7.86 %
7.06 %
6.24 %
5.87 %
5.70 %
5.65 %
5.29 %
5.17 %
5.10 %
5.23 %
5.12 %
5.10 %
5.05 %
Others
20.75 %
21.29 %
18.34 %
18.16 %
17.57 %
17.19 %
16.94 %
15.45 %
15.85 %
16.89 %
17.27 %
1.23 %
1.23 %
1.26 %
1.15 %
1.10 %
1.10 %
1.05 %
0.94 %
0.93 %
1.06 %
No of Share Holders
0
2,93,782
3,02,292
3,61,288
3,61,862
3,78,547
3,82,828
3,78,011
3,60,677
3,22,678
2,89,074
2,81,542
2,80,248
2,88,537
2,79,280
2,81,988
2,83,210
2,86,604
2,80,256
2,88,931
2,90,411

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 7.5 5 5 6 6.5 4 4 8 12 0.00
Dividend Yield (%) 1.02 0.68 0.85 0.59 0.87 0.61 0.25 0.39 0.52 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
28 Jul 2021 DIVIDEND Dividend
₹ 6.50 /share
 27 Jul 2021 1,212.25 1,111.60
15 Jul 2022 DIVIDEND Dividend
₹ 4.00 /share
 14 Jul 2022 683.30 643.20
14 Jul 2023 DIVIDEND Dividend
₹ 4.00 /share
 14 Jul 2023 732.25 930.75
16 Jul 2024 DIVIDEND Dividend
₹ 8.00 /share
 16 Jul 2024 1,655.25 1,832.10
02 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 02 Aug 2024 1,778.90 1,953.55
07 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 07 Nov 2024 2,151.95 2,166.05
11 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 11 Feb 2025 2,134.25 2,169.40
14 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 14 May 2025 2,107.70 2,063.00
25 Jul 2025 DIVIDEND Dividend
₹ 12.00 /share
 25 Jul 2025 2,063.00 1,943.40
05 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 05 Aug 2025 1,930.85 1,882.20
11 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 11 Aug 2025 1,894.70 1,918.00
06 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 06 Nov 2025 1,943.35 1,997.00
12 Feb 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 12 Feb 2026 2,150.50 2,209.10
07 May 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 07 May 2026 2,311.50 2,442.90

Announcements

Compliances-Reg.24(A)-Annual Secretarial Compliance1 day ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release2 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release3 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release6 days ago
Announcement under Regulation 30 (LODR)-Earnings Call Transcript7 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release8 days ago
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 09, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 08, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationMay 07, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 07, 2026
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sMay 07, 2026
Corporate Action-Board approves DividendMay 07, 2026
Board Meeting Outcome for The Audited Financial Results For The Quarter And Year Ended March 31 2026 And Recommendation Of Final Dividend Of Rs. 18 /- Per Equity Share I.E. 900 % Of The Face Value Of Rs. 2/- Each Fully Paid Up For The Financial Year EndedMay 07, 2026
Approval Of The Audited Financial Statements For The Quarter And Year Ended March 31 2026 And Recommend Final Dividend Of Rs. 18/- Per Equity Share I.E. 900% Of The Face Value Of Rs. 2/- Each Fully Paid Up For The Financial Year Ended March 31 2026May 07, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 05, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 05, 2026
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 04, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 23, 2026
Board Meeting Intimation for Considering And Approving The Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Year Ended March 31 2026 And Recommend Dividend If Any.Apr 22, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 22, 2026
U.S. FDA Has Concluded An Inspection At The Companys Manufacturing Facility Located In Somerset New Jersey U.S.A.Apr 18, 2026
Announcement under Regulation 30 (LODR)-AcquisitionApr 17, 2026
Settlement Agreement.Apr 17, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 10, 2026
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSApr 09, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 08, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 07, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 07, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 06, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 02, 2026
Acquisition Of Minority Shareholding In Multicare Pharmaceuticals Philippines Inc.Apr 01, 2026
Announcement under Regulation 30 (LODR)-Updates on AcquisitionApr 01, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 31, 2026
Buyback Of Shares By Multicare Pharmaceuticals Philippines Inc. A Subsidiary Company.Mar 30, 2026
Closure of Trading WindowMar 25, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 25, 2026
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 24, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 19, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 17, 2026
U.S. FDA Has Concluded An Inspection At Our Manufacturing Facility At Ankleshwar India.Mar 07, 2026
Newspaper Publication For The Information Regarding Special Window For Transfer And Dematerialization Of Physical Shares.Mar 07, 2026
Disclosure Pursuant To Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015.Mar 02, 2026
Announcement under Regulation 30 (LODR)-Updates on AcquisitionFeb 27, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 27, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)Feb 26, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 26, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 26, 2026
Disclosure Pursuant To Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 25, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 24, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 23, 2026

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
ICICI Prudential Active Momentum Fund Direct-Growth
0.00%
-195905
-2.68%
-2.54%
Sundaram Multi-Factor Fund Direct-Growth
1.47%
60376
1.47%
1.47%
Abakkus Flexi Cap Fund Direct-Growth
2.24%
44000
-0.23%
-0.05%
Capitalmind Flexi Cap Fund Direct-Growth
1.93%
15307
0.67%
1.93%
Bandhan Multi-Factor Fund Direct-Growth
3.92%
12068
-0.06%
1.42%
Bandhan Healthcare Fund Direct-Growth
2.78%
-10000
-1.03%
-0.73%
Samco Mid Cap Fund Direct-Growth
2.72%
8641
2.72%
2.72%
ITI Business Cycle Fund Direct-Growth
0.00%
-7165
-1.79%
0.00%
Groww Multi Asset Allocation Fund Direct-Growth
0.21%
-3269
-0.22%
-0.57%
Unifi Dynamic Asset Allocation Fund Direct-Growth
0.00%
-2125
-0.04%
-0.04%
Tata Nifty Midcap 150 Index Fund Direct-Growth
1.44%
1353
-0.18%
-0.04%
Franklin India Multi-Factor Fund Direct-Growth
1.26%
1231
-0.12%
-0.09%
Edelweiss Nifty LargeMidcap250 Plus 8-13 Yr G-Sec 70:30 Index Fund Direct-Growth
0.51%
933
0.51%
0.51%
JioBlackRock Nifty Midcap 150 Index Fund Direct-Growth
1.43%
-651
-0.19%
-0.05%
Kotak Active Momentum Fund Direct-Growth
1.60%
494
-0.17%
0.04%
DSP Nifty Healthcare Index Fund Direct-Growth
5.53%
367
-0.29%
-0.03%
UTI Nifty500 Shariah Index Fund Direct-Growth
1.00%
354
-0.08%
0.01%
Zerodha Nifty LargeMidcap250 Plus 8-13 Yr G-Sec 70:30 Index Fund Direct-Growth
0.51%
334
0.51%
0.51%
Kotak Nifty Midcap 150 Index Fund Direct-Growth
1.45%
276
-0.09%
-0.02%
Zerodha Nifty MidSmallcap400 50:50 Index Fund Direct-Growth
0.72%
245
0.72%
0.72%
JioBlackRock Sector Rotation Fund Direct-Growth
0.39%
196
-0.05%
-0.02%
Nippon India Nifty India Manufacturing Index Fund Direct-Growth
1.44%
111
-0.15%
0.00%
DSP Nifty Midcap 150 Index Fund Direct-Growth
1.43%
85
-0.17%
-0.04%
Groww Nifty Midcap 150 Index Fund Direct-Growth
1.43%
32
-0.20%
-0.04%
Motilal Oswal BSE 1000 Index Fund Direct-Growth
0.28%
27
-0.03%
0.01%

Technical Indicators

RSI(14)
Neutral
47.68
ATR(14)
Less Volatile
59.28
STOCH(9,6)
Neutral
28.63
STOCH RSI(14)
Neutral
29.82
MACD(12,26)
Bearish
-5.69
ADX(14)
Weak Trend
12.49
UO(9)
Bearish
50.24
ROC(12)
Downtrend But Slowing Down
-2.51
WillR(14)
Neutral
-73.92
Bearish
5
Neutral
4
Bullish
0

About Lupin

Lupin is a global pharmaceutical company producing branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. Founded in 1983, it operates in over 100 markets, specializing in cardiovascular, diabetology, asthma, pediatric, central nervous system, gastrointestinal, anti-infective, and NSAID therapies. Lupin is a leader in anti-TB and cephalosporins segments. The...more
Website
https://www.lupin.com/
Chairperson NameM D Gupta
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Fundamental Screeners
Technical Screeners
Intraday Screeners
Price & Volume Screeners
Candlestick Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.
We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.
This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.
The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.
We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.
This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.
By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.
We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.

© 2025 - 2026 Raise Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104